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Significant opportunities and challenges are presented when
transitioning from managing laboratory automation development
of pharmaceutical products at a single site to collaborative
management with multiple domestic and international sites. Prior
to integrating Glaxo and Burroughs Wellcome about two years
ago, each company had expertise in laboratory automation, but
neither had a strategy for consistent business-justified laboratory
automation. The approach for international harmonization of
automation development of pharmaceutical test methods that the
integrated company has adopted is presented. Some items to
consider before undertaking a company-wide automation develop-
ment harmonization programme are offered for consideration.
Experiences encountered andfuture planned benefits are discussed.
Introduction
The environment within today’s pharmaceutical industry
is one of tough, world-wide competition in international
markets. For a large, international company like Glaxo-
Wellcome to be successful, high efficiency must be
obtained through the organization. It is important to
reduce the time from clinical trials to the launch of a
product. It would be most effective to minimize duplica-
tion of effort and maximize standardization of work
practices within the company. One way that the analy-
tical chemistry testing areas can gain efficiency is to
automate labour intensive or technique-dependent activ-
ities. As part of this effort, harmonizing the development
of automated test methods should be considered. In order
to put this into practice, many activities must be co-
ordinated between testing and development laboratories.
This task is complicated for a company like GlaxoWell-
come by the fact that it has many distant laboratories
with different cultures and/or regulatory drivers which
are developing methods for the same products. This
means that there is a risk that the harmonization process
will be slow, frustrating, and non-productive. However, if
planned and managed well, appropriate alignment with
other analytical groups can proceed smoothly and pro-
ductively.
Before establishing the programme at GlaxoWell-
come
Since there is more than one group developing laboratory
automation for the same products at GlaxoWellcome, it
was worth considering harmonization of automated
methodology. Before work was started on a standardized
company-wide laboratory automation development pro-
cess, the following items considered:
What is the potential business value of automated
test methods in the company?
What is the scope of the harmonization plan; which
laboratories will be involved?
What is the magnitude of the overlapping automa-
tion needs in other testing groups?
What efficiencies could be gained by one team co-
ordinating the development of automated test
methods?
How flexible can each testing laboratory be regard-
ing the final automation solution?
Can the same test method be used at all of the sites?
Is any group ’married’ to specific technologies or
suppliers?
What is the cost of transferring non-standard auto-
mated test methods to the testing laboratories?
What is the benefit of having automated test
methods available earlier in the product life cycle,
prior to NDA stability studies and NDA/MAA
registration?
With existing staff, how long will it take to develop/
maintain/enhance specific automated methods at
each site independently?
What are the regulatory compliance benefits ofhav-
ing different laboratories using identical automated
test methods on common products?
A business justification was required in order to evaluate
if the harmonization effort would be worthwhile. Many
assumptions about different items had to be made. The
accuracy of those assumptions will greatly influence how
close the estimated net benefit will be to the actual
benefit. It was therefore important to try to get accurate
estimations when building the cost/benefit model for the
programme. Some items considered were:
Number of products tested at multiple sites.
Number of batches of each product tested at each
site.
Number ofmethods to be automated for those prod-
ucts.
Sample flow into the lab.
Time period required to test manually.
Analyst’s time required to test manually.
Time period required to test using automation.
Analyst’s time required to test using automation.
Number of batches that can be tested manually per
analyst per day.
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Percentage of the analyst’s time dedicated to man-
ual testing.
Number of batches that can be tested using auto-
mation per analyst per day.
Percentage of the analyst’s time dedicated to auto-
mated testing.
Cost of equipment to test manually.
Cost of automated equipment.
Cost of analyst’s time.
Other operating costs such as supplies, service,
maintenance.
Depreciation rate.
There needs to be a clear achievable advantage in
investing in a harmonization programme. A broad
assessment of the potential net value of the program
was provided for management’s evaluation. One point
that was emphasized was that the standardization process
is a significant undertaking, requiring substantial re-
sources to establish and maintain. The costs and benefits
of this undertaking were estimated based on assumptions
which were our best estimates as to what the business
would look like in the future. Benefits include:
Redundant automation development will be mini-
mized within the operation.
A superior infrastructure (validation protocols, doc-
umentation, etc.) will be developed.
Consistency of various practices will be maximized
across sites which will minimize regulatory compli-
ance issues.
Efficiency of transfer of automated methods
between groups will be maximized.
Automation solutions will be achieved faster and at
the right time.
Superior automation solutions will be realized.
Automated solutions will become available which
could not be justified at individual sites.
Education on automation technology and about
other areas of the company will increase.
Contacts to discuss automation problems/opportu-
nities with will increase.
Agreements on common technology platforms can
result in a stronger negotiating position with sup-
pliers.
The opportunity for staff development will increase.
Potential risks/costs include:
Conflict may arise between groups (not invented
here’, personality conflicts, inadequate agreement
up front, different support levels from participants,
etc.).
There may be different priority/timing require-
ments between groups.
There may be different preferences in technology
and/or suppliers between groups.
The best technology solution may not be supported
at all times.
The compromises required to harmonize may not
be worth the gains.
The equipment and/or software versions/upgrades
may be difficult to co-ordinate.
The time and costs required to develop/sustain the
process may be considerable.
Team members may be caught between opposite
pressures coming from local site business needs
and the automation team.
Sufficient resources may not be available to develop
standard infrastructure.
The automation solutions including hardware and
software may be expensive.
Once management support is obtained, the implementa-
tion plan with estimated costs and benefits including
assumptions should be documented. This document
should also contain the commitments from the manage-
ment that are needed for success.
Establishing the harmonized laboratory automa-
tion programme
Before starting to build a harmonized automation pro-
gramme, the key players need to agree on a basic goal.
The goal was to develop a common process to create
efficient, rugged automated test methods using one
common development/validation protocol on a common
equipment/software platform, which meets the business
needs of all of the collaborating testing laboratories.
Harmonization does not have to be an all-or-nothing
situation. Before starting the standardization effort, each
group needed to consider to what degree they wanted to
harmonize.
At GlaxoWellcome, an international automation har-
monization strategy (IAHS) group was established com-
prising managers of quality control and development
groups from several major sites. A balance between the
development and user groups was established, as well as a
balance between members from Europe, North America,
etc. The members of the IAHS group were all technically
oriented, but not currently hands-on testers or develo-
pers. This group was responsible for reporting to a more
general international science board comprising man-
agers, directors and vice presidents. The initial role of
the IAHS group was to establish high level goals, develop
a high level strategy, identify automation areas to har-
monize and to develop a model to measure the net value
of this effort.
There were a number of basic tasks to be considered by
the IAHS group when developing the standardized
laboratory automation development process. The opti-
mum timing and order of these will vary from organ-
ization to organization. Some of the tasks that IAHS
group addressed were:
Present the proposal to targeted laboratory groups
to determine their interests.
Agree on basic goals, assumptions and models to
calculate costs and benefits.
Supply senior management at each site with a jus-
tification for the harmonization project.
Set up communication links.
Establish a mission statement.
Identify major automation areas to be addressed.
Select team members and leaders for each focus
area.
Provide guidance and support to focus teams.
Monitor and communicate progress of focus teams.
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After a mission statement, general objectives and guiding
principals were established, several areas of opportunity
for laboratory automation development harmonization
were identified. For each identified area (solid dosage
forms, metered dose inhalers, etc.), focus teams were
created to address the standardization of automation
development. Each focus team was assigned two sponsors
who were IAHS group team members, normally one
from the development area and one from the testing
area. The role of the IAHS group sponsor is to provide
high level direction and to ensure that these focus teams
are accomplishing the overall goals of the harmonization
effort. Focus team responsibilities included:
Agree on common technology platforms (hardware
and software).
Agree on how upgrades will be managed.
Agree on common practices covering: laboratory
instrument qualification; method validation proto-
cols and reports; method transfer protocols and
reports; acceptance criteria for method validation
and transfers.
Establish communication links between the team
members and with the strategy group sponsors.
Assess the automation needs and resources available
to develop automated methods.
Identify and prioritize specific automation projects
using business acceptance criteria.
Establish milestones and timelines for specific pro-
jects.
Ensure that specific automation projects stay on
track.
Share existing automation solutions.
Communicate details of automation projects in pro-
gress.
The members of the GlaxoWellcome focus teams are a
mix of first line supervisors and hands-on scientists from
both development and testing laboratories. They will
either work on automation projects themselves or direct
the work of others who are assigned to the projects. The
focus teams have defined the detailed common infra-
structure components for harmonized technology. Two
co-leaders are assigned for each team so that both the
development and quality control areas are adequately
represented.
Our experience to date
The IASH group has been formally meeting since
October 1996. This group has representatives from
development and quality control in North America,
Europe and Japan and meets quarterly with a video
conference approximately half-way between meetings.
The face-to-face meetings are aligned as much as possible
with other quarterly analytical meetings to minimize
travel time and expenses. The IAHS team has identified
several focus areas and three focus teams are fully
functional at this time with significant progress achieved
in two areas.
Metered dose inhaler (MDI) focus team
One focus team is working on developing automated test
methods for metered dose inhalers. There was an in-
formal international team already in existence before the
official automation development harmonization effort
was launched. The focus group sponsors agreed that
the existing team needed no change in membership in
order to meet the IAHS group’s objectives. The existing
team’s goals were aligned well with the company’s
automation needs, so no adjustments to the team’s
activities were required. A second chairperson was as-
signed to this focus team so that both the quality control
and development areas were represented in the leader-
ship. This team has only met face-to-face once, shortly
after officially forming. They normally hold a video
conference meeting every four to six weeks. A common
shared area on a universal server has been set up so that
information is easily accessible to all members. The IAHS
group sponsors keep in touch with the focus team’s
progress which is communicated to the IAHS group
periodically. There are two areas that are being ad-
dressed by the metered dose inhaler focus team.
The first analytical application that was addressed had
two different automation solutions already far into devel-
opment by two different groups. Since one of the sol-
utions was a relatively inexpensive partially automated
solution and the other was a more expensive fully auto-
mated solution, it was decided that both projects would
be completed. The focus team has tied up all the loose
ends for both projects and equipment is currently being
fabricated for several testing laboratories. Although all
the sites had influenced both final automated solutions,
the day to day running of each project was run by only
one group. It was felt that this made each project run
more efficiently. It is encouraging to see that sites have
already ordered equipment that was developed by the
’other’ site.
The second area that is being addressed by the metered
dose inhaler focus team was not as far along in develop-
ment as the first. A requirements document was devel-
oped by the focus group and has been distributed to
potential manufacturers of the hardware for bidding
purposes. The team will select a vendor based on their
responses to the requirements document, considering
items such as capabilities, service, price, time to delivery,
etc. Although this project is currently being managed at
only one site, considerable input continues to be provided
by several sites. Since there is a high level of trust within
the team, this approach seems to be working very well
and all team members are satisfied with this mode of
operation.
Solid dosageform focus team
Another focus team is concentrating on content uniform-
ity and dissolution analysis of solid dosage forms. This
team was established after the formation of the IAHS
team. From the beginning, this team has been in align-
ment with the automation standardization process. Com-
mon technical platforms, validation protocols and
acceptance criteria have been agreed upon. Since differ-
ent analytical groups were using different versions of
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software, a standard version of software has been selected
for each type of hardware. Once all participating labora-
tories have installed the common hardware platform and
software version, existing automated methods will be
transferred to other testing sites. Their focus team is also
currently agreeing on priorities to determine which new
or current manual methods will be developed on the
common platforms. Each testing lab can decide which of
their existing methods will be aligned with the common
platforms and which will be left alone.
The future
uniformity samples, manual testing would be performed
using an equivalent stand-alone homogenizer instead of
the traditional shaker or sonicator. The quality control
lab will not have to develop and validate a new set of
automated test methods in order to test effectively. This
will free up quality control resources by allowing samples
to be tested efficiently at the time of production intro-
duction and avoiding lengthy post-launch method im-
provement projects. The method transfers to quality
control at that time will be efficient and straightforward,
since the hardware and software platforms will be iden-
tical to that on which the method was developed.
When standard equipment platforms and software ver-
sions have been installed and new methods are being
developed and validated using standard protocols, there
will be minimal resources required to maintain the
harmonized automation development process. The focus
team will only need to meet periodically (about every six
months) to consider the value in upgrading hardware,
software, or standard protocols as improved technology
emerges and regulatory or laboratory requirements
change.
When a harmonized approach to automated testing and
development is adopted, it will be to the company’s
advantage to develop automated test methods well before
the product goes to market. This will allow the clinical
supplies, NDA stability batches, process validation sam-
ples and early commercial release and stability batches to
be tested efficiently. Also, there should be complete
correlation in the assay data from the development
stage through the end of the product life. The assay
specifications for the product would then also be based
on data generated with the same systems that will be used
to test samples throughout its product life cycle.
The test methods going into the regulatory submissions
will be automated test methods. Any manual testing
would be performed with hardware that is equivalent
to the automated hardware. For example, if the auto-
mated equipment employed a homogenizer for content
Conclusion
A lot of planning is needed to achieve a harmonized
laboratory automation development process in a multi-
site company. However, if good team players from both
development and testing laboratories are involved and
this process is supported by upper management, harmon-
ization is achievable. Once the process is in place, a
company would have efficient automated test methods
that meet the testing laboratory’s needs through the
product life cycle. These methods would be easily
transferred to other testing laboratories in the company.
There would no longer be several sets of different test
methods being developed and validated for one product
in different laboratories. There would be no issues ofdata
not corresponding to data generated in other participat-
ing laboratories and the possibility of data not corre-
sponding to the product specifications. At this time, we
have enough experience with the automation develop-
ment harmonization process to have full confidence that
the benefits will be well worth the effort.
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